Hansa Biopharma to present data at 2024 American Transplant Congress annual meeting

Contributed by: PR Newswire

Tags

Hansa-Biopharma

More Like This

Hansa Biopharma presents positive outcomes of five-year follow-up study of imlifidase in kidney transplantation at ESOT Congress 2025 in London

Hansa Biopharma to attend 2025 J.P. Morgan Healthcare Conference

Hansa hosts call with distinguished transplant surgeons: Insights on clinical practice and imlifidase Phase 3 Results

Hansa Biopharma Reports Third Quarter and Interim Year to Date 2025 Financial Results

Hansa Biopharma Submits BLA to FDA for Imlifidase in desensitization for Kidney Transplantation

Hansa Biopharma completes enrolment in European Phase 3 20-HMedIdeS-19 Post Authorization Efficacy and Safety study in highly sensitized kidney transplant patients

Hansa Biopharma's Biologics License Application (BLA) for imlifidase accepted by the FDA

PDUFA Action Date for Hansa Biopharma's Imlifidase BLA Set for December 19, 2026